{"version":"1.0","type":"link","title":"Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).","author_name":"Malorni L 외","author_url":"https://prs-insight.online/author/Malorni%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/87532","thumbnail_width":1200,"thumbnail_height":630}